SABS
SAB Biotherapeutics, Inc.NASDAQHealthcare$3.85-0.77%ClosedMarket Cap: $36.8M
As of 2026-04-07
Valuation
P/E (TTM)
5.64
PEG
0.02
P/B
0.49
P/S
0.00
EV/EBITDA
1.94
DCF Value
$0.04
FCF Yield
-124.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
15.2%
ROA
7.7%
ROIC
-30.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-15.8M | $-16.9M | $-0.81 | — |
| FY 2025 | $0.00 | -Infinity% | $-49.0M | $13.3M | $-0.79 | — |
| Q3 2025 | $0.00 | -Infinity% | $-12.7M | $45.4M | $-0.21 | — |
| Q2 2025 | $0.00 | -Infinity% | $-9.7M | $-10.1M | $-1.09 | — |
| Q1 2025 | $0.00 | -Infinity% | $-10.8M | $-5.2M | $-0.56 | — |
| Q4 2024 | $114.7K | -585.0% | $-10.0M | $-11.4M | $-1.23 | — |
| FY 2024 | $1.3M | -262.4% | $-42.9M | $-34.1M | $-3.68 | — |
| Q3 2024 | $0.00 | -Infinity% | $-11.3M | $-10.3M | $-1.12 | — |
| Q2 2024 | $263.1K | -288.4% | $-10.2M | $-7.3M | $-0.79 | — |
| Q1 2024 | $944.6K | -110.1% | $-11.4M | $-5.0M | $-0.54 | — |
| Q4 2023 | $305.0K | -209.5% | $-18.9M | $-22.9M | $-3.86 | — |
| FY 2023 | $2.2M | -67.3% | $-38.1M | $-42.2M | $-7.64 | — |